Table 1.
Characteristics of the study cohort.
| Total (n = 300) |
Without MAbs (n = 145) |
With MAbs (n = 155) |
Adj. P-valuea | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Sex, n (%) | ||||
| Female | 262 (87.3%) | 132 (91.0%) | 130 (83.9%) | 0.219 |
| Mean ± SD, y | 47.1 ± 11.6 | 45.7 ± 12.5 | 48.3 ± 10.7 | 0.208 |
| Age, n (%) | ||||
| <30 y | 28 (9.3%) | 18 (12.4%) | 10 (6.5%) | 0.240 |
| 30–39 y | 38 (12.7%) | 16 (11.0%) | 22 (14.2%) | |
| 40–49 y | 106 (35.3%) | 55 (37.9%) | 51 (32.9%) | |
| 50–59 y | 91 (30.3%) | 41 (28.3%) | 50 (32.3%) | |
| ≥60 y | 37 (12.3%) | 15 (10.3%) | 22 (14.2%) | |
| Migraine treatment | ||||
| Concomitant preventive treatment, n (%) | 254 (84.7%) | 126 (86.9%) | 128 (82.6%) | 0.386 |
| Adherence to preventive treatmentb, n (%) | 231/254 (90.9%) | 106/126 (84.1%) | 125/128 (97.6%) | 0.008 |
| Adherence to MAbsb, n (%) | N/A | N/A | 147 (94.8%) | N/A |
| Response to acute medication, n (%) | 207 (69.0%) | 95 (65.5%) | 112 (72.3%) | 0.320 |
| COVID-19 | ||||
| COVID-19 casesc, n (%) | 41 (13.7%) | 16 (11.0%) | 25 (16.1%) | 0.320 |
| Previous history of pneumonia, n (%) | 63 (21.0%) | 29 (20.0%) | 34 (21.9%) | 0.777 |
In bold are marked statistically significant variables (P value ≤ 0.05).
a
Adjusted P value with Benjamini–Hochberg procedure.
b
Period starting from Feb 1st, 2020 until participants’ submission of the survey.
c
Participants with confirmed SARS-CoV-2 real-time reverse transcriptase polymerase-chain reaction (RT-PCR) assay by nasopharyngeal swabs or with >2 of the COVID-19 symptoms either in the absence of a confirmatory test or with negative RT-PCR assay.
MAbs = anti-CGRP monoclonal antibodies; SD = standard deviation; N/A = not applicable.